- Home
- SGLY vs DRMA Comparison
SGLY vs DRMA Comparison
Compare SGLY & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- DRMA
- Stock Information
- Founded
- SGLY 2001
- DRMA 2014
- Country
- SGLY United States
- DRMA United States
- Employees
- SGLY N/A
- DRMA N/A
- Industry
- SGLY
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- SGLY
- DRMA Health Care
- Exchange
- SGLY Nasdaq
- DRMA Nasdaq
- Market Cap
- SGLY 5.8M
- DRMA 6.1M
- IPO Year
- SGLY 2008
- DRMA 2021
- Fundamental
- Price
- SGLY $0.83
- DRMA $1.25
- Analyst Decision
- SGLY
- DRMA Strong Buy
- Analyst Count
- SGLY 0
- DRMA 1
- Target Price
- SGLY N/A
- DRMA $6.00
- AVG Volume (30 Days)
- SGLY 3.3M
- DRMA 465.7K
- Earning Date
- SGLY 02-19-2025
- DRMA 03-20-2025
- Dividend Yield
- SGLY N/A
- DRMA N/A
- EPS Growth
- SGLY N/A
- DRMA N/A
- EPS
- SGLY N/A
- DRMA N/A
- Revenue
- SGLY $2,255,541.00
- DRMA N/A
- Revenue This Year
- SGLY N/A
- DRMA N/A
- Revenue Next Year
- SGLY N/A
- DRMA N/A
- P/E Ratio
- SGLY N/A
- DRMA N/A
- Revenue Growth
- SGLY N/A
- DRMA N/A
- 52 Week Low
- SGLY $0.66
- DRMA $1.00
- 52 Week High
- SGLY $7.65
- DRMA $7.62
- Technical
- Relative Strength Index (RSI)
- SGLY 36.06
- DRMA 52.68
- Support Level
- SGLY $0.78
- DRMA $1.00
- Resistance Level
- SGLY $0.95
- DRMA $1.28
- Average True Range (ATR)
- SGLY 0.17
- DRMA 0.09
- MACD
- SGLY -0.00
- DRMA 0.01
- Stochastic Oscillator
- SGLY 18.80
- DRMA 74.07
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.